TOP > 外国特許検索 > PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN

PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN

外国特許コード F170009027
整理番号 (S2015-1633-N0)
掲載日 2017年3月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP071899
国際公開番号 WO 2017026276
国際出願日 平成28年7月26日(2016.7.26)
国際公開日 平成29年2月16日(2017.2.16)
優先権データ
  • 特願2015-156726 (2015.8.7) JP
発明の名称 (英語) PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN
発明の概要(英語) In order to establish a means for selectively delivering a large amount of boron to a tumor tissue, provided is a pharmaceutical composition containing a conjugate of a compound represented by formula (I): X-L-Y (in the formula, X represents a group including 10B, L represents a linker, and Y represents a group bound to a lysine residue), and a tumor-accumulative protein having a lysine residue, wherein the molar ratio (mol number of the compound/mol number of the protein) of the compound and protein contained in the composition exceeds 10.
従来技術、競合技術の概要(英語) BACKGROUND ART
Boron neutron capture therapy (Boron Neutron Capture Therapy; BNCT) is, a low energy thermal neutrons are harmless to the human body with boron was captured by a drug, thermal neutrons10 Bby reaction, in the microenvironment to one cell line α with lithium to generate new cells destroyed cancer cancer therapy.
Low energy thermal neutrons and fast neutrons have a higher energy level is different from, but are harmless to the human body, thermal neutrons10 Breaction, resulting in lithium and helium nuclei (α line), and about 2.4MeV 1 such energy is sufficient to destroy the cells of one energy.
Is an ideal method of treatment of cancer, without a significant obstacle in the normal tissue, and kill cancer cells, the effective BNCT in order to obtain a therapeutic effect on cancer cells selectively boron needs to be delivered.
Immature angiogenesis around the tumor tissue, a characteristic that is easily accumulated fine particles such as liposomes (EPR effect, is Enhanced permeation and retention effect). Based on this characteristic, using liposome delivery system of boron to cancer cells has been developed. For example, the inventors of the present invention, to a second lipid bilayer of the liposome is introduced into the boron compound, can be a very high concentration boron delivery has succeeded in the development of systems (non-patent document 1). In addition, a boron compound is introduced also in the liposome membrane, by introducing a boron compound, the high integration of the boron (non-patent document 2) successful.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO INSTITUTE OF TECHNOLOGY
  • 発明者(英語)
  • NAKAMURA, Hiroyuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
詳しくお知りになりたい方は下記「問合せ先」まで直接お問合わせください

PAGE TOP

close
close
close
close
close
close